In this Motley Fool Live video recorded on March 26, healthcare and cannabis bureau chief Corinne Cardina and Fool.com contributor Adria Cimino discuss Moderna‘s (NASDAQ: MRNA) coronavirus vaccine trial in kids — and what that population may mean for revenue.
This Could Be a New Billion-Dollar Market for Moderna
Latest from Blog
Amazon.com (NASDAQ: AMZN) has moved into healthcare through its acquisition of PillPack and the potential of…
3D Systems (NYSE: DDD) is slated to report its first-quarter 2021 results after the market close…
Elastic‘s (NYSE: ESTC) stock price more than doubled over the past 12 months, as the Dutch…
Deep discount retailer Dollar General (NYSE: DG) is going on a hiring spree next week, holding…
Netflix (NASDAQ: NFLX) is no longer the only game in town in streaming television, and the…